Advocacy intelligence hub — real-time data for patient organizations
European Institute of Oncology
Metrogel: FDA approved
Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Metrogel
(Metronidazole (topical))Orphan drugGalderma Laboratories, Inc.
Nitroimidazole Antimicrobial [EPC]
12.1 Mechanism of Action The mechanism of action of metronidazole in the treatment of rosacea is unknown.
Browse all Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas news →
Sandip P Patel
SWOG Cancer Research Network
📍 Birmingham, Alabama
Sarah B Whittle
Pediatric Early Phase Clinical Trial Network
Mark Stevens, Phd
Travera Inc
Rob Kimmerling, Phd
Travera Inc
Sebastien Hotte
University Health Network-Princess Margaret Hospital
Scot C. Remick, MD, MD
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
📍 SCARBOROUGH, ME
View all Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas specialists →